Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

被引：21

作者：

Zobniw, Chrystia M. ^{[1
]}

Causebrook, Alanna ^{[2
]}

Fong, Mei Ka ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Dept Pharm, Elm & Carlton St, Buffalo, NY 14263 USA

[2] Erie Coll Osteopath Med, Sch Pharm, Erie, PA USA

来源：

RESEARCH AND REPORTS IN UROLOGY | 2014年 / 6卷

关键词：

glucocorticoid receptor; CYP17; pipeline; enzalutamide; sipuleucel-T; drug resistance; radium-223; dichloride;

D O I：

10.2147/RRU.S29003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.

引用

页码：97 / 105

页数：9

共 50 条

[21] Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer
Hoy, Sheridan M.
DRUGS, 2013, 73 (18) : 2077 - 2091
[22] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
Becker, Daniel J.
Iyengar, Arjun D.
Punekar, Salman R.
Ng, Jason
Zaman, Anika
Loeb, Stacy
Becker, Kevin D.
Makarov, Danil
ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
[23] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
Zhang, Tian
Zhu, Jason
George, Daniel J.
Armstrong, Andrew J.
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
[24] Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
Fallara, Giuseppe
Robesti, Daniele
Raggi, Daniele
Montorsi, Francesco
Necchi, Andrea
Cooperberg, Matthew R.
Malavaud, Bernard
Ploussard, Guillaume
Martini, Alberto
EUROPEAN UROLOGY OPEN SCIENCE, 2023, 52 : 40 - 43
[25] Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
Eryilmaz, Melek Karakurt
Karaagac, Mustafa
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2031 - 2034
[26] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
Banna, Giuseppe L.
Urzia, Valeria
Benanti, Chiara
Pitre, Alessandra
Lipari, Helga
Di Quattro, Rosario
De Giorgi, Ugo
Schepisi, Giuseppe
Basso, Umberto
Bimbatti, Davide
Rundo, Francesco
Libra, Massimo
Malatino, Lorenzo
SUPPORTIVE CARE IN CANCER, 2020, 28 (10) : 4687 - 4695
[27] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
Giuseppe L. Banna
Valeria Urzia
Chiara Benanti
Alessandra Pitrè
Helga Lipari
Rosario Di Quattro
Ugo De Giorgi
Giuseppe Schepisi
Umberto Basso
Davide Bimbatti
Francesco Rundo
Massimo Libra
Lorenzo Malatino
Supportive Care in Cancer, 2020, 28 : 4687 - 4695
[28] Treatment of metastatic, castration-resistant prostate cancer
von Amsberg, G.
Merseburger, A. S.
UROLOGE, 2020, 59 (06): : 673 - 679
[29] PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer
Burgio, Salvatore L.
Conteduca, Vincenza
Rudnas, Britt
Carrozza, Francesco
Campadelli, Enrico
Bianchi, Emanuela
Fabbri, Paolo
Montanari, Marco
Carretta, Elisa
Menna, Cecilia
De Giorgi, Ugo
CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 39 - 43
[30] Abiraterone acetate in castration-resistant prostate cancer
Iacovelli, Roberto
Palazzo, Antonella
Procopio, Giuseppe
Gazzaniga, Paola
Cortesi, Enrico
ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254

← 1 2 3 4 5 →